利爾化學(002258.SZ)全資子公司草銨膦原藥生產線停產併線
格隆匯12月25日丨利爾化學(002258.SZ)公佈,為進一步優化廣安利爾草銨膦原藥等主要產品的生產工藝,並順利實現與甲基二氯化磷項目的併線,以提升產品的工藝技術水平與競爭力,廣安利爾實施此次停產併線,預計時間約3個月。
公告稱,廣安利爾此次停產併線,將有助於提升草銨膦原藥的市場競爭力,從而提升公司的綜合效益。雖然公司已提前做了相應的準備,但預計此次停產還是會減少草銨膦原藥的產量,從而將對公司2020年1季度及2020年全年經營業績產生一定不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.